Similarly, in mice bearingLLC-derived xenograft tumors, in vivo administration of anti-B7-H1antibody significantly increased the total number of spleen and tumor T cellscompared to levels in control mice that did not receive anti-B7-H1 antibody.Functionally, in vivo administration of anti-B7-H1 antibody markedlyreduced tumor growth. Here, CD80 is linked to neoplasm.